Lipocine Inc.: Lipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment Milestone

Second Drug Safety Monitoring Board (DSMB) meeting update planned for mid-January 2026 Topline results on track for the second quarter of 2026 SALT LAKE CITY, ...

Kyverna Therapeutics: "Strong Buy" Rating As Positive SPS Data Leads To 1st Half 2026 BLA Filing

Kyverna Therapeutics stock upgraded to Strong Buy after positive phase 2 results for miv-cel in SPS and MG. Read the latest ...

FDA ready to initiate new projects for organized development of Faisalabad: DG Asif Ch

Director General (DG) Muhammad Asif Chaudhry has said that FDA is ready to initiate new projects under Public-Private ...
The Herald Journal

Lipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment Milestone

Second Drug Safety Monitoring Board (DSMB) meeting update planned for mid-January 2026Topline results on track for the second ...